{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:08:29Z","timestamp":1790089709857,"version":"4.0.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myelodysplastic syndromes (MDS) with isolated deletion of chromosome 5q [MDS-del(5q)] constitute a distinct biological entity traditionally associated with favorable outcomes, although up to one-quarter of patients progress to acute myeloid leukemia (AML). Existing prognostic models, developed in heterogeneous MDS populations, may not adequately capture risk within this subgroup. We assembled an international cohort of 682 patients with MDS-del(5q) to evaluate the performance of the Revised International Prognostic Scoring System (IPSS-R) and its molecular version (IPSS-M), identify prognostic variables, and develop a disease-specific prognostic tool, the IPSS-del(5q). Most patients were classified as lower risk by IPSS-R (94.4%) and IPSS-M (85.5%), yet both systems showed limited discriminatory ability (concordance indices [C-indices] \u22480.5). Independent adverse prognostic factors included age of \u226570 years, male sex, anemia (hemoglobin \u226410 g\/dL), thrombocytopenia (platelet count \u2264100 \u00d7 109\/L), the presence of 1 additional chromosomal abnormality, \u22652 gene mutations, SF3B1 mutations, and high-risk TP53 status. Six variables were included in the IPSS-del(5q), stratifying patients into standard-risk (74.3%) and high-risk (25.7%) groups with significantly different leukemia-free survival (69.2 months vs 32.0 months, respectively; P&amp;lt; .01). Moreover, this model reclassified 19.1% of patients in lower-risk IPSS-R group and 14.6% of those in lower-risk IPSS-M group into the high-risk IPSS-del(5q) group. However, its discriminative power remained modest, with a C-index of 0.60. Overall, to our knowledge, this study provides the most comprehensive prognostic evaluation of MDS-del(5q) to date, demonstrates the limited discriminatory capacity of existing MDS scores in this entity, and underscores the need to develop refined disease-specific prognostic approaches for this MDS subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020633","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:55:02Z","timestamp":1784296502000},"page":"6178-6187","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9532-7417","authenticated-orcid":false,"given":"Maria Julia","family":"Montoro","sequence":"first","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[{"name":"2Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Acha","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"3Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"4MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1961","authenticated-orcid":false,"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[{"name":"5Malignant Hematology Program, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-5422","authenticated-orcid":false,"given":"Yasuo","family":"Kubota","sequence":"additional","affiliation":[{"name":"6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Schulz","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7975-8223","authenticated-orcid":false,"given":"Robert","family":"Briski","sequence":"additional","affiliation":[{"name":"8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla H","family":"Al Ali","sequence":"additional","affiliation":[{"name":"5Malignant Hematology Program, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-1307","authenticated-orcid":false,"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Institut Catal\u00e0 d\ua78cOncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lopez-Cadenas","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"10Department of Hematology, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-5475","authenticated-orcid":false,"given":"Anna Aguilera","family":"Romero","sequence":"additional","affiliation":[{"name":"2Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[{"name":"3Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Naomi","family":"Eder","sequence":"additional","affiliation":[{"name":"11Clinic of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, Georg August University of G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Jerez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hung","family":"Wang","sequence":"additional","affiliation":[{"name":"12Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-759X","authenticated-orcid":false,"given":"Alessia","family":"Campagna","sequence":"additional","affiliation":[{"name":"13Department of Biomedical Sciences, Humanitas Clinical and Research Center-IRCCS, and Humanitis University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-8829","authenticated-orcid":false,"given":"Luca","family":"Lanino","sequence":"additional","affiliation":[{"name":"13Department of Biomedical Sciences, Humanitas Clinical and Research Center-IRCCS, and Humanitis University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Betz","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"14MDS Unit, Department of Hematology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa","family":"Bernal","sequence":"additional","affiliation":[{"name":"15Hospital Universitario Central de Asturias, Instituto Universitario de Oncolog\u00eda del Principado de Asturias, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-403X","authenticated-orcid":false,"given":"Esperanza","family":"Such","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Hospital Universitario La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-4941","authenticated-orcid":false,"given":"Anne Sophie","family":"Kubasch","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[{"name":"18Yale Cancer Center, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"},{"name":"19Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3540-8556","authenticated-orcid":false,"given":"Carla","family":"Zindel","sequence":"additional","affiliation":[{"name":"20Service d'H\u00e9matologie S\u00e9niors, H\u00f4pital Saint-Louis, Universite de Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"21King's College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"20Service d'H\u00e9matologie S\u00e9niors, H\u00f4pital Saint-Louis, Universite de Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael","family":"Sekeres","sequence":"additional","affiliation":[{"name":"22Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8641-6415","authenticated-orcid":false,"given":"Sangeetha","family":"Venugopal","sequence":"additional","affiliation":[{"name":"22Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas D\u00edaz","family":"Varela","sequence":"additional","affiliation":[{"name":"15Hospital Universitario Central de Asturias, Instituto Universitario de Oncolog\u00eda del Principado de Asturias, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"23Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[{"name":"12Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"18Yale Cancer Center, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"20Service d'H\u00e9matologie S\u00e9niors, H\u00f4pital Saint-Louis, Universite de Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Maria","family":"Diez-Campelo","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-1402","authenticated-orcid":false,"given":"Daniel H","family":"Wiseman","sequence":"additional","affiliation":[{"name":"12Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-5970","authenticated-orcid":false,"given":"Matteo G","family":"Della Porta","sequence":"additional","affiliation":[{"name":"13Department of Biomedical Sciences, Humanitas Clinical and Research Center-IRCCS, and Humanitis University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"5Malignant Hematology Program, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-2161","authenticated-orcid":false,"given":"Francesc","family":"Sol\u00e9","sequence":"additional","affiliation":[{"name":"3Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"4MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6271","authenticated-orcid":false,"given":"Laura","family":"Palomo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"9Department of Hematology, Institut Catal\u00e0 d\ua78cOncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-078X","authenticated-orcid":false,"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"20","key":"2026092210525578500_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026092210525578500_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.391","article-title":"Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study","volume":"26","author":"Germing","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2026092210525578500_bib3","first-page":"339","article-title":"Myelodysplastic syndromes with isolated del(5q): a unique disease entity","volume":"97","author":"Ad\u00e8s","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2026092210525578500_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2010.231","article-title":"Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q","volume":"25","author":"Mallo","year":"2011","journal-title":"Leukemia"},{"issue":"14","key":"2026092210525578500_bib5","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low- or intermediate-1\u2013risk myelodysplastic syndromes with del(5q)","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026092210525578500_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.leu.2403189","article-title":"Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31","volume":"18","author":"Giagounidis","year":"2004","journal-title":"Leukemia"},{"issue":"15","key":"2026092210525578500_bib7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092210525578500_bib8","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/ajh.26845","article-title":"TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): a Mayo\u2013Moffitt study of 156 informative cases","volume":"98","author":"Fleti","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2026092210525578500_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","article-title":"Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact","volume":"102","author":"Meggendorfer","year":"2017","journal-title":"Haematologica"},{"issue":"16","key":"2026092210525578500_bib10","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.2024023840","article-title":"Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion","volume":"144","author":"Montoro","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026092210525578500_bib11","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/j.clml.2022.01.002","article-title":"Therapeutic outcomes and prognostic impact of gene mutations including TP53 and SF3B1 in patients with del(5q) myelodysplastic syndromes","volume":"22","author":"Chan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026092210525578500_bib12","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/leu.2015.49","article-title":"Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q","volume":"29","author":"Heuser","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2026092210525578500_bib13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2026092210525578500_bib14","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2026092210525578500_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"14","key":"2026092210525578500_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092210525578500_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2018.07.019","article-title":"The IPSS-R has prognostic impact in untreated patients with MDS del(5q)","volume":"72","author":"Kaivers","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"2026092210525578500_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41118-022-00171-9","article-title":"Patterns in age and cause of death contribution to the sex gap in life expectancy: a comparison among ten countries","volume":"78","author":"Feraldi","year":"2022","journal-title":"Genus"},{"issue":"13","key":"2026092210525578500_bib19","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2026092210525578500_bib20","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026092210525578500_bib21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2013.085217","article-title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes","volume":"99","author":"Bejar","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2026092210525578500_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026092210525578500_bib23","first-page":"1200","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"140","author":"Khoury","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026092210525578500_bib24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026092210525578500_bib25","first-page":"1448","article-title":"Patients with low-blast MDS and TP53 multihit alterations have worse outcomes than patients with MDS-del(5q) and TP53 multihit alterations","volume":"40","author":"Montoro","year":"2026","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6178\/2588278\/blooda_adv-2026-020633-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6178\/2588278\/blooda_adv-2026-020633-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:53:07Z","timestamp":1790088787000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6178\/569754\/Comprehensive-analysis-of-prognostic-factors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020633","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,10]]}}}